REG - ValiRx PLC - Extension of Evaluation Agreement

ValiRxAnnouncement

30/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250130:nRSd1893Va&default-theme=true

RNS Number : 1893V  ValiRx PLC  30 January 2025

30 January 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Extension of Evaluation Agreement

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update on the Evaluation Agreement with the University of Dundee and their
Drug Discovery Unit announced on 12 February 2024.

The Evaluation Agreement under the Overarching agreement with Dundee
University focuses on investigating a lead series of therapeutic candidates in
the increasingly important research area of pro-senescence (selectively
promoting ageing of cancer cells to cease growth in tumours).

The evaluation process for this project in the Inaphaea BioLabs facility
continues to demonstrate activity but specialist techniques are required to
complete the mechanism of action studies. ValiRx have agreed a one year
extension with the University of Dundee until 9 February 2026 to continue the
mechanism of action studies which will be provided by the research group of
Professor Cleo Bishop (Professor of Senescence and Director of the Queen Mary
University London Phenotypic Screening Facility), supported by a £50,000
grant from the Queen Mary University London Impact Fund and £9,000 from
ValiRx.

The Directors of the Company take responsibility for this announcement.

Mark Eccleston, CEO of ValiRx commented "We are pleased with the
demonstration of activity for the compounds under evaluation in Inaphaea's
lab. A key decision point for in-licensing the asset is determination of the
precise mechanism of action of the asset which requires access to techniques
and equipment that we do not currently possess. We are fortunate to be working
with Professor Bishop and have worked with her to secure non-dilutive funding
to undertake the required work."

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investorhub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement                                      https://valirx.com/link/DP4BGe

 We encourage all investors to share questions on this announcement via our
 investor hub

 ValiRx plc                                                                   Tel: +44 115 784 0025

                                                                              www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                                                       Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)                             Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)                                     Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                                               +44 (0) 115 787 0206

                                                                              www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                                          lucy@vformation.biz

                                                                              sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSEIFAUEISEFF